iShares MSCI Australia ETF vs Vaxcyte Inc. Common Stock — how do they compare? iShares MSCI Australia ETF trades at $28.55 (market cap $1.20B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 8.8× iShares MSCI Australia ETF's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, iShares MSCI Australia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 61 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| EWA | PCVX | |
|---|---|---|
Market Cap | $1.20B | $10.51B |
Volume | 1,742,887 | 2,644,694 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $73.82 |
52-Week Low | $24.95 | $40.32 |
Typical Hold Time | 61 Days | 0 Days |
Enterprise Value | — | $9.14B |
Signals from Pluang's Aura AI — not financial advice
EWA, the iShares MSCI Australia ETF, trades at $28.77, up 0.35% today, but technical indicators signal a bearish trend with moving averages and key oscillators like the 6-day RSI at 75.94 suggesting overbought conditions. The ETF tracks Australian equities, heavily weighted toward commodities and financials, with recent news highlighting institutional selling by Squarepoint Ops LLC amid broader market concerns over inflation and oil price volatility.
The outlook for EWA hinges on commodity demand and global economic trends, offering exposure to Australia's resource-driven economy but facing risks from inflation and geopolitical tensions. Analyst sentiment is mixed, with Seeking Alpha rating it a Buy targeting over 20% upside, while technical weakness and institutional selling pose near-term headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →